Who
Anthony J. Japour
Director
Company insider
Files Form 4 as: Director, Cocrystal Pharma; Director, Opko Health.
In numbers
- Trades disclosed
- 10
- Buys
- 2
- Sells
- 0
- Bought
- $1,490
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 6 Jan 2020
- Last trade
- 9 Jan 2026
- Last filed
- 13 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jan 2026filed 13 Jan 2026 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,410 at $0.00 | filing |
| 9 Jan 2026filed 13 Jan 2026 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,410 at $0.00 | filing |
| 9 Oct 2024filed 11 Oct 2024 | COCP Cocrystal PharmaBiotechnology | SEC FORM 4 Code A | —14,924 | filing |
| 18 Jul 2023filed 20 Jul 2023 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,567 at $0.00 | filing |
| 25 Jul 2022filed 3 Aug 2022 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —148,000 at $0.00 | filing |
| 16 Jul 2021filed 20 Jul 2021 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 22 Jun 2020filed 24 Jun 2020 | COCP Cocrystal Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 12 Mar 2020filed 13 Mar 2020 | OPK Opko HealthBiotechnology | SEC FORM 4 Bought | $755500 at $1.51 | filing |
| 3 Mar 2020filed 4 Mar 2020 | OPK Opko HealthBiotechnology | SEC FORM 4 Bought | $735500 at $1.47 | filing |
| 6 Jan 2020filed 8 Jan 2020 | OPK Opko Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthOPK · prnewswire.com · 15 Oct 2026
0 headlines in the last 90 days name Anthony J. Japour; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.